SNY CHMP opinion: Thursday, September 17, 2026
Variation type II · WAYRILZ · A grouped application consisting of: C.12: Submission of the final report from study LUNA-2 (PRN1008 010), listed as a category 3 study in the RMP. This is a Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of Rilzabrutinib, an Oral Bru
Dates are sourced from official registries and filings and can change — estimated dates (marked ~) slip routinely. This page updates automatically when the source registry moves the date. Research information only, not investment advice.
Every date on this page is free — forever.
A free account adds the interactive calendar with US/EU filters and watchlists. Investor (€19/mo) adds Impact Forecasts on each event, date-slip tracking and calendar sync (Google/Apple/Outlook). Pro adds the full analytics stack.